Skip to main content
BIOA logo

BIOA

BioAge Labs, Inc.

$4.29

9.02%

Trade Ideas Performance

Latest Closed Trade Idea

$4.29

9.02%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

3

Social

72

About

Events of BioAge Labs, Inc. (BIOA)

In May 2026, Roth Capital initiated coverage with a 'Buy' rating. In June 2026, executives discussed plans for BGE-102, with near-term readouts expected in cardiovascular risk and diabetic macular edema. August 2026 saw the company report a wider net loss despite a marginal increase in collaboration-based revenue, and the first participant was dosed in the QUELL-DME Phase 2 trial for BGE-102. In September 2026, BioAge Labs initiated the Phase 2 QUELL-DME trial. UBS initiated coverage with a 'Neutral' rating in October 2026. Most recently, in November 2026, BioAge Labs reported a third-quarter net loss of $33.5 million and collaboration revenue of $0.3 million, missing analyst estimates, primarily due to a $1.7 million adjustment from a September 2026 Novartis agreement amendment. The company anticipates QUELL-CV Phase 2 results in Q4 2026 and QUELL-DME Phase 2 results in H2 2027, and plans to submit its first IND application for an APJ program by year-end 2026. A significant event in December 2024 was the termination of the STRIDES Phase 2 study for azelaprag due to elevated liver enzymes, which caused a more than 76% stock price drop and led to securities class action lawsuits alleging misleading statements related to its September 2024 IPO.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)